Orangeburg, New York – July 28, 2015 – Impulse Dynamics (USA), Inc. announced that Cardiac electrophysiologist, Andrew Kaplan, M.D., FACC, FHRS became the first physician in the United States to implant the Optimizer™ IVs investigational device as part of the FIX-HF-5C FDA IDE protocol in a heart failure patient with a previously implanted subcutaneous (under the skin) implantable cardioverter defibrillator or S-ICD. (link CVAM) “It is exciting that as new technologies emerge we are able to see that the Impulse Dynamics technology is compatible with them: a true testament to the planning and engineering that went into the design process of the Optimizer,” said Dr. Kaplan.

About the Optimizer™ IVs System and CCM Therapy

The Optimizer™ IVs device delivers Cardiac Contractility Modulation (CCM) therapy , a unique and innovative method for treating moderate to severe heart failure, by delivering non-excitatory pulses to the heart using transvenous leads. It is available in cardiology centers throughout Europe and various other locations. The device has been implanted in over 2500 patients and is the only device therapy available for patients with narrow QRS complex. Impulse Dynamics has completed numerous clinical studies, including several randomized controlled trials. The results have been published in over 60 publications in leading medical journals. The Optimizer™ IVs System is limited to Investigational use only in the United States.

About Impulse Dynamics

Impulse Dynamics N.V. is focused on the development of electrical therapies for the treatment of chronic heart failure.  As a global leader in cardiac medical innovation, Impulse Dynamics has operations in the US, Europe, Asia and Australia.  For more information please visit www.impulse-dynamics.com